Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice

RenalytixAI Announces Podium Presentation and Publication on “Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression”

Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease   NEW YORK, March 24, 2020 /PRNewswire/ —  Renalytix AI plc (LSE: RENX),  the AIM-traded developer of

Read More

Published
Categorized as News

RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference

NEW YORK, March 2, 2020 /PRNewswire/ —  Renalytix AI plc  (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the  Cowen 40th Annual Health Care Conference  taking place on March 1-4, 2020, at the Boston Marriott

Read More

Published
Categorized as News

Medicare Sets National Price for KidneyIntelX™

NEW YORK, Dec. 3, 2019 /PRNewswire/ —  Renalytix AI plc  (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services (“CMS”) has released the Final 2020 Clinical Laboratory Fee Schedule

Read More

Published
Categorized as News

U.S. CPT® Code Granted for KidneyIntelX™

CPT Code a key component for reimbursement from private medical insurance and Medicare   NEW YORK, July 1, 2019 /PRNewswire/ —  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical

Read More

Published
Categorized as News

Study Published in Journal of Clinical Investigation Insight Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology

Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need NEW YORK, June 7, 2019 /PRNewswire/ —  Renalytix AI plc  (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

Read More

Published
Categorized as News


Well Filtered™

Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.